127 related articles for article (PubMed ID: 12059987)
1. Allelic polymorphism -491A/T in apo E gene modulates the lipid-lowering response in combined hyperlipidemia treatment.
García-Otín AL; Civeira F; Aristegui R; Díaz C; Recalde D; Sol JM; Masramon X; Hernández G; Pocoví M;
Eur J Clin Invest; 2002 Jun; 32(6):421-8. PubMed ID: 12059987
[TBL] [Abstract][Full Text] [Related]
2. Genetic variation in the hepatic lipase gene is associated with combined hyperlipidemia, plasma lipid concentrations, and lipid-lowering drug response.
Cenarro A; Artieda M; Gonzalvo C; Meriño-Ibarra E; Arístegui R; Gañán A; Díaz C; Sol JM; Pocoví M; Civeira F;
Am Heart J; 2005 Dec; 150(6):1154-62. PubMed ID: 16338252
[TBL] [Abstract][Full Text] [Related]
3. Chitotriosidase genotype and serum activity in subjects with combined hyperlipidemia: effect of the lipid-lowering agents, atorvastatin and bezafibrate.
Canudas J; Cenarro A; Civeira F; Garcí-Otín AL; Arístegui R; Díaz C; Masramon X; Sol JM; Hernández G; Pocoví M
Metabolism; 2001 Apr; 50(4):447-50. PubMed ID: 11288040
[TBL] [Abstract][Full Text] [Related]
4. The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate.
Christidis DS; Liberopoulos EN; Kakafika AI; Miltiadous GA; Cariolou M; Ganotakis ES; Mikhailidis DP; Elisaf MS
J Cardiovasc Pharmacol Ther; 2006 Sep; 11(3):211-21. PubMed ID: 17056835
[TBL] [Abstract][Full Text] [Related]
5. Contribution of apo CIII reduction to the greater effect of 12-week micronized fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipidemic patients.
Lemieux I; Salomon H; Després JP
Ann Med; 2003; 35(6):442-8. PubMed ID: 14572169
[TBL] [Abstract][Full Text] [Related]
6. A comparative study of the efficacy of simvastatin and gemfibrozil in combined hyperlipoproteinemia: prediction of response by baseline lipids, apo E genotype, lipoprotein(a) and insulin.
Nestel P; Simons L; Barter P; Clifton P; Colquhoun D; Hamilton-Craig I; Sikaris K; Sullivan D
Atherosclerosis; 1997 Mar; 129(2):231-9. PubMed ID: 9105566
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia.
Melenovsky V; Malik J; Wichterle D; Simek J; Pisarikova A; Skrha J; Poledne R; Stavek P; Ceska R
Am Heart J; 2002 Oct; 144(4):E6. PubMed ID: 12360175
[TBL] [Abstract][Full Text] [Related]
8. A promoter polymorphism in cholesterol 7alpha-hydroxylase interacts with apolipoprotein E genotype in the LDL-lowering response to atorvastatin.
Kajinami K; Brousseau ME; Ordovas JM; Schaefer EJ
Atherosclerosis; 2005 Jun; 180(2):407-15. PubMed ID: 15910869
[TBL] [Abstract][Full Text] [Related]
9. MTP gene polymorphisms and postprandial lipemia in familial combined hyperlipidemia: effects of treatment with atorvastatin.
Klop B; Verseyden C; Ribalta J; Salazar J; Masana L; Cabezas MC
Clin Investig Arterioscler; 2014; 26(2):49-57. PubMed ID: 24378322
[TBL] [Abstract][Full Text] [Related]
10. Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia.
Gómez-Gerique JA; Ros E; Oliván J; Mostaza JM; Vilardell M; Pintó X; Civeira F; Hernández A; da Silva PM; Rodriguez-Botaro A; Zambón D; Lima J; Díaz C; Aristegui R; Sol JM; Chaves J; Hernández G;
Atherosclerosis; 2002 Jun; 162(2):245-51. PubMed ID: 11996943
[TBL] [Abstract][Full Text] [Related]
11. Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner.
Pedro-Botet J; Schaefer EJ; Bakker-Arkema RG; Black DM; Stein EM; Corella D; Ordovas JM
Atherosclerosis; 2001 Sep; 158(1):183-93. PubMed ID: 11500190
[TBL] [Abstract][Full Text] [Related]
12. Apolipoprotein E polymorphism influences lipid phenotypic expression, but not the low density lipoprotein subfraction distribution in familial combined hyperlipidemia.
Bredie SJ; Vogelaar JM; Demacker PN; Stalenhoef AF
Atherosclerosis; 1996 Oct; 126(2):313-24. PubMed ID: 8902157
[TBL] [Abstract][Full Text] [Related]
13. Atorvastatin monotherapy vs. combination therapy in the management of patients with combined hyperlipidemia.
Avisar I; Brook JG; Wolfovitz E
Eur J Intern Med; 2008 May; 19(3):203-8. PubMed ID: 18395165
[TBL] [Abstract][Full Text] [Related]
14. Apolipoprotein E mRNA expression in mononuclear cells from normolipidemic and hypercholesterolemic individuals treated with atorvastatin.
Cerda A; Genvigir FD; Willrich MA; Arazi SS; Bernik MM; Dorea EL; Bertolami MC; Faludi AA; Hirata MH; Hirata RD
Lipids Health Dis; 2011 Nov; 10():206. PubMed ID: 22074026
[TBL] [Abstract][Full Text] [Related]
15. Effects of atorvastatin on postprandial plasma lipoproteins in postinfarction patients with combined hyperlipidaemia.
Boquist S; Karpe F; Danell-Toverud K; Hamsten A
Atherosclerosis; 2002 May; 162(1):163-70. PubMed ID: 11947910
[TBL] [Abstract][Full Text] [Related]
16. Complex genetic contribution of the Apo AI-CIII-AIV gene cluster to familial combined hyperlipidemia. Identification of different susceptibility haplotypes.
Dallinga-Thie GM; van Linde-Sibenius Trip M; Rotter JI; Cantor RM; Bu X; Lusis AJ; de Bruin TW
J Clin Invest; 1997 Mar; 99(5):953-61. PubMed ID: 9062353
[TBL] [Abstract][Full Text] [Related]
17. Effects of atorvastatin and omega-3 fatty acids on LDL subfractions and postprandial hyperlipemia in patients with combined hyperlipemia.
Nordøy A; Hansen JB; Brox J; Svensson B
Nutr Metab Cardiovasc Dis; 2001 Feb; 11(1):7-16. PubMed ID: 11383326
[TBL] [Abstract][Full Text] [Related]
18. Effect of statins on LDL particle size in patients with familial combined hyperlipidemia: a comparison between atorvastatin and pravastatin.
Sirtori CR; Calabresi L; Pisciotta L; Cattin L; Pauciullo P; Montagnani M; Manzato E; Bittolo Bon G; Fellin R
Nutr Metab Cardiovasc Dis; 2005 Feb; 15(1):47-55. PubMed ID: 15871851
[TBL] [Abstract][Full Text] [Related]
19. Influence of microsomal triglyceride transfer protein promoter polymorphism -493 GT on fasting plasma triglyceride values and interaction with treatment response to atorvastatin in subjects with heterozygous familial hypercholesterolaemia.
García-García AB; González C; Real JT; Martín de Llano JJ; González-Albert V; Civera M; Chaves FJ; Ascaso JF; Carmena R
Pharmacogenet Genomics; 2005 Apr; 15(4):211-8. PubMed ID: 15864113
[TBL] [Abstract][Full Text] [Related]
20. Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia.
Maki KC; Bays HE; Dicklin MR; Johnson SL; Shabbout M
J Clin Lipidol; 2011; 5(6):483-92. PubMed ID: 22108152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
